hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06263400, orgStudyIdInfo id: randomized trial, briefTitle: Recovery Levels of Depression Patients and Caregiver Psychoeducation, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-09-01, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Aydin Adnan Menderes University, class: OTHER, descriptionModule briefSummary: To determine the effect of psychoeducation given to patients and caregivers on patients' depression and recovery levels, caregivers' emotional expression and family burden levels., conditionsModule conditions: Psychoeducation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: In randomization, among the patients who volunteered to participate in the study, the odd number of patients and their caregivers in the list made according to the order of hospitalization constituted the study group, and the even number of patients and their caregivers formed the control group., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 92, type: ESTIMATED, armsInterventionsModule interventions name: psychoeducation and follow-up study, outcomesModule primaryOutcomes measure: to patients before training, primaryOutcomes measure: pre-training caregivers, secondaryOutcomes measure: after training, secondaryOutcomes measure: after training, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: AydınAdnan Menderes University, Faculy of Nursing, Division Public Health Nursing, status: RECRUITING, city: Aydın, state: Aydın/Turkey, zip: 09000, country: Turkey, contacts name: şerife öztaban, MsC, role: CONTACT, phone: +905557130105, email: serifeoztaban@gmail.com, contacts name: Filiz ADANA, Phd, role: SUB_INVESTIGATOR, geoPoint lat: 37.84501, lon: 27.83963, hasResults: False
protocolSection identificationModule nctId: NCT06263361, orgStudyIdInfo id: NCH02-2021, briefTitle: Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma., statusModule overallStatus: RECRUITING, startDateStruct date: 2021-10-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: IRCCS San Raffaele, class: OTHER, descriptionModule briefSummary: Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non- Hodgkin lymphoma exclusively localized into the nervous system. The aim of this study is to evaluate the MRI imaging characteristics of the peritumoral area (PTA) and to correlate this information to pathological findings., conditionsModule conditions: Cerebral Lymphoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: MRI imaging, interventions name: Cerebral biopsy, outcomesModule primaryOutcomes measure: MRI imaging, primaryOutcomes measure: MRI imaging, primaryOutcomes measure: MRI imaging, primaryOutcomes measure: MRI imaging, primaryOutcomes measure: Define immunopathological features, secondaryOutcomes measure: Accuracy of fluoresceine guided stereotactic biopsy, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS San Raffaele Scientific Institute, status: RECRUITING, city: Milan, zip: 20132, country: Italy, contacts name: Laura Sincinelli, role: CONTACT, phone: 003926435568, email: sincinelli.laura@hsr.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06263348, orgStudyIdInfo id: HMM0601, briefTitle: A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-20, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-04-30, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Hua Medicine Limited, class: INDUSTRY, collaborators name: Shanghai Branch, KunTuo Medical Research and Development (Beijing) Co., Ltd., descriptionModule briefSummary: The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin., conditionsModule conditions: Type2diabetes, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The marketed product - Dorzagliatin tablet (HuaTangNing®) is used as the study drug. During this study, the dosage and administration of Dorzagliatin tablets will be completely in accordance with the investigator's judgment based on the package insert and the patient's condition., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 2000, type: ESTIMATED, armsInterventionsModule interventions name: Dorzagliatin tablets, outcomesModule primaryOutcomes measure: Incidences of ADRs and SAEs, secondaryOutcomes measure: Blood glucose indicators, secondaryOutcomes measure: Response rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: China-Japan Friendship Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100029, country: China, contacts name: Wenying Yang, MD,PhD, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, locations facility: China-Japan Friendship Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100029, country: China, contacts name: Bo Zhang, MD,PhD, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06263335, orgStudyIdInfo id: Fatima Jinnah Women University, briefTitle: MBI for Psychological Distress, SI and NSSI Among Young Adults, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-02-28, primaryCompletionDateStruct date: 2022-05-28, completionDateStruct date: 2022-05-28, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Fatima Jinnah Women University, class: OTHER, descriptionModule briefSummary: Designed to measure the impact of Mindfulness Based Intervention on depression, anxiety, stress, psychological distress, Suicidal Ideation, Non-Suicidal Self Injury urge and Mindfulness in young adults. Those individuals who agree to participate in the trial and identified with high levels of psychological distress and Suicidal Ideation, randomly divided into interventional (n=30) and control (n=30) groups. The Mindfulness Based Stress Reduction intervention then administered to the interventional group for eight weeks and pre and post intervention assessment done for both the groups., conditionsModule conditions: Psychological Distress, conditions: Suicidal Ideation, conditions: Non-Suicidal Self Injury, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Mindfulness Based Stress Reduction Intervention, outcomesModule primaryOutcomes measure: Psychological Distress, primaryOutcomes measure: Suicidal Ideation, primaryOutcomes measure: Non-Suicidal Self-Injury (NSSI), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 24 Years, stdAges: ADULT, contactsLocationsModule locations facility: Fatima Jinnah Women University, city: Rawalpindi, state: Punjab, zip: 46000, country: Pakistan, geoPoint lat: 33.6007, lon: 73.0679, hasResults: False
protocolSection identificationModule nctId: NCT06263322, orgStudyIdInfo id: IRB202200419, secondaryIdInfos id: R21AG073769, type: NIH, link: https://reporter.nih.gov/quickSearch/R21AG073769, briefTitle: The ROAMM-EHR Study, acronym: ROAMM-EHR, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-16, primaryCompletionDateStruct date: 2026-10-17, completionDateStruct date: 2026-10-17, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: University of Florida, class: OTHER, collaborators name: National Institute on Aging (NIA), descriptionModule briefSummary: In recent years, mobile health (mHealth) apps have promised improved monitoring of health conditions to improve clinical outcomes. The objective of this study is to conduct a pilot randomized clinical trial (RCT) to evaluate the impact of using remotely collected patient generated health data (PGHD) from older patients undergoing bypass surgery due to chronic limb threatening ischemia. The hypothesis is that integrating PGHD with an EHR system will help providers manage post-surgical symptoms and thus improve post-operative mobility and quality of life health outcomes., conditionsModule conditions: Peripheral Arterial Disease, conditions: Chronic Limb-Threatening Ischemia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Parallel Randomized Clinical trial. Comparison study to test the feasibility of patient generated health data compared to standard of care post-surgical observation., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: QUADRUPLE, maskingDescription: Participants are masked to whether their PGHD are being sent to their care provider. Care providers are masked to who receives standard of care. Investigators (except for one who will be the point person for randomization) will be masked to intervention assignments. Staff assessors will be masked to whether PGHD are being sent to their care provider., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Actionable remotely generated health data, interventions name: Non-Actionable remotely generated health data, outcomesModule primaryOutcomes measure: 6-min walk distance, secondaryOutcomes measure: self-reported quality of life, eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Institute of Aging, status: RECRUITING, city: Gainesville, state: Florida, zip: 32611, country: United States, contacts name: Institute_of_Aging, role: CONTACT, phone: 352-273-5919, email: recruit@aging.ufl.edu, contacts name: HOBI_Department, role: CONTACT, phone: 352.627.9467, email: hobi@health.ufl.edu, geoPoint lat: 29.65163, lon: -82.32483, hasResults: False
protocolSection identificationModule nctId: NCT06263309, orgStudyIdInfo id: Femoralneckfracture, briefTitle: Mid-Term Radiological Outcomes of Femoral Neck Fractures Treated With Osteosynthesis: A Comparative Analysis, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-06-01, primaryCompletionDateStruct date: 2023-06-01, completionDateStruct date: 2023-09-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Istanbul University, class: OTHER, descriptionModule briefSummary: OBJECTIVES: This study assesses the efficacy of dynamic hip screw (DHS) versus cannulated screws for femoral neck fractures, focusing on femoral neck shortening, avascular necrosis (AVN) incidence, and functional outcomes.METHODS:Design: Retrospective cohort study. Setting: Academic Level I Trauma Center. Patient Selection Criteria: Included were patients with femoral neck fractures treated with DHS or cannulated screws, with follow-up data available.Outcome Measures and Comparisons: Main outcomes were femoral neck shortening, incidence of AVN, and Harris Hip Score (HHS) for functional assessment., conditionsModule conditions: Femoral Neck Fractures, conditions: Femoral Neck Shortening, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 10, type: ACTUAL, armsInterventionsModule interventions name: Femoral neck shortening measurement, outcomesModule primaryOutcomes measure: Harris Hip score, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University, city: İstanbul, zip: 34093, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06263244, orgStudyIdInfo id: NL83403.018.22, briefTitle: Specifying the Anti-inflammatory Effects of Ziltivekimab, acronym: SPIDER, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), class: OTHER, descriptionModule briefSummary: The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics., conditionsModule conditions: Atherosclerosis, conditions: Inflammation, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized, double blind, placebo-controlled trial, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, maskingDescription: After informed consent has been obtained, patients will be randomized via computer randomization to either 15 mg ziltivekimab (n=20) or placebo (n=20). On the eCRFs or other documents subjects will be identified by subject ID and randomization number only., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Ziltivekimab, interventions name: Placebo, outcomesModule primaryOutcomes measure: TBRmax coronary arteries, primaryOutcomes measure: monocyte activation marker protein expression, secondaryOutcomes measure: delta PCAT, secondaryOutcomes measure: Correlation delta TBRmax and CCTA derived plaque characteristics, secondaryOutcomes measure: delta SUVmax bone marrow, secondaryOutcomes measure: delta TBRmax ascending aorta, secondaryOutcomes measure: changes monocyte phenotype, secondaryOutcomes measure: changes in hsCRP, secondaryOutcomes measure: changes plasma cytokine and chemokine levels (pg/mL), secondaryOutcomes measure: changes plasma cytokine and chemokine levels (ng/mL), eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06263231, orgStudyIdInfo id: IT-03, briefTitle: A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3), acronym: INVINCIBLE-3, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2027-12, completionDateStruct date: 2028-12, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Intensity Therapeutics, Inc., class: INDUSTRY, collaborators name: Premier Research Group plc, descriptionModule briefSummary: To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen., conditionsModule conditions: Sarcoma,Soft Tissue, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 333, type: ESTIMATED, armsInterventionsModule interventions name: INT230-6, interventions name: Eribulin, interventions name: Trabectedin, interventions name: Pazopanib, outcomesModule primaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Overall Survival (OS) For INT230-6 Compared to OS for Standard of Care (SOC) for Participants with leiomyosarcoma, secondaryOutcomes measure: Overall Survival (OS) For INT230-6 Compared to OS for Standard of Care (SOC) for Participants with liposarcoma, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06263218, orgStudyIdInfo id: CCR-2023-200344, briefTitle: Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-12-29, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Hospital do Rim e Hipertensão, class: OTHER, descriptionModule briefSummary: This is a single-center, non-interventional, retrospective study of data, at the level of the individual without identification, extracted from medical records of adult patients undergoing a kidney transplant procedure after 1st from January 2018 until reaching the sample size enrollment (around 500 individuals); this refers to the period of verification of individuals' eligibility for entry into the study. Individuals under strategy preemptive patients who developed CMV infection/disease within 12 months after transplantation. The data will be collected from date of transplant (including pre-transplant clinical history) until completion of at least 12 months after transplantation, or until graft loss, or recipient death or loss to follow-up, when/if applicable., conditionsModule conditions: CMV Infection, conditions: CMV Viremia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 500, type: ESTIMATED, outcomesModule primaryOutcomes measure: Incidence of infection, CMV disease, and tissue invasive disease., secondaryOutcomes measure: Incidence recurrent CMV infection/disease, secondaryOutcomes measure: Incidence of refractory CMV infection/disease, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital do Rim, city: São Paulo, zip: 04038-002, country: Brazil, geoPoint lat: -23.5475, lon: -46.63611, hasResults: False
protocolSection identificationModule nctId: NCT06263205, orgStudyIdInfo id: Dressing, briefTitle: Wound Management Following Gl Tumor Surgery: Comparing Outcomes of Dressing Changes Versus Non-Dressing Techniques, acronym: Dressing, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-01-24, completionDateStruct date: 2026-12-24, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, collaborators name: Shanghai Changzheng Hospital, collaborators name: Changhai Hospital, collaborators name: Shanghai East Hospital, descriptionModule briefSummary: The goal of this clinical trial is to assess the effectiveness and safety of non-dressing (exposed wound) versus dressing techniques in postoperative wound management for patients with gastrointestinal tumors. The main questions it aims to answer are:1. Does non-dressing of postoperative wounds in gastrointestinal tumor surgery provide equivalent or better wound healing compared to traditional dressing techniques?2. Can non-dressing of postoperative wounds reduce patient pain and healthcare costs? Participants in this study, who are diagnosed with gastrointestinal tumors and undergoing surgery, will be randomly assigned to either the non-dressing group or the dressing group. The non-dressing group will have their surgical wounds left exposed after initial postoperative care, while the dressing group will receive regular wound dressing changes every 48-72 hours. Researchers will compare these two groups to see if there are differences in the rate of wound complications, pain levels, and overall healthcare costs.This study aims to provide evidence-based recommendations for postoperative wound care in gastrointestinal tumor surgeries, potentially improving patient outcomes and reducing medical expenses., conditionsModule conditions: Gastrointestinal Tumors, conditions: Surgical Wound Infection, conditions: Pain, Postoperative, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 816, type: ESTIMATED, armsInterventionsModule interventions name: Non-Dressing of Surgical Wound, interventions name: Regular Dressing Change of Surgical Wound, outcomesModule primaryOutcomes measure: Rate of Postoperative Wound Healing Complications, secondaryOutcomes measure: Patient Pain Levels, secondaryOutcomes measure: Medical Costs Associated with Wound Care, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fudan University Shanghai Cancer Center, city: Shanghai, state: Shanghai, zip: 2000000, country: China, contacts name: Dazhi Xu, MD,PHD, role: CONTACT, phone: 021-64175590, email: xudzh@shca.org.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06263192, orgStudyIdInfo id: AMH-IUI, briefTitle: Pregnancy Prediction Using Anti-Müllerian Hormone in Intrauterine Insemination Cycles, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-10-01, primaryCompletionDateStruct date: 2022-12-01, completionDateStruct date: 2023-05-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Jose Antonio Moreno, class: OTHER, collaborators name: Universitat Autonoma de Barcelona, descriptionModule briefSummary: The goal of this study is to compare the cumulative pregnancy rates after 4 artificial inseminations with donor (IAD) in non-sterile women with plasma AMH levels \> and \< 1.1 ng/mL., conditionsModule conditions: Infertility, Female, conditions: Anti-Mullerian Hormone Deficiency, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 342, type: ACTUAL, armsInterventionsModule interventions name: Intrauterine insemination, outcomesModule primaryOutcomes measure: Cummulative pregnancy rate, eligibilityModule sex: FEMALE, minimumAge: 25 Years, maximumAge: 39 Years, stdAges: ADULT, contactsLocationsModule locations facility: Fertty International, city: Barcelona, zip: 08010, country: Spain, geoPoint lat: 41.38879, lon: 2.15899, hasResults: False